Hikma Pharmaceuticals Plc Rating Reiterated by Barclays (HIK)
Shares of Hikma Pharmaceuticals Plc (LON:HIK) opened at 1752.00 on Thursday. Hikma Pharmaceuticals Plc has a one year low of GBX 1004.00 and a one year high of GBX 1835.00. The stock’s 50-day moving average is GBX 1736. and its 200-day moving average is GBX 1583.. The company’s market cap is £3.465 billion.
Other equities research analysts have also recently issued reports about the stock. Analysts at Jefferies Group raised their price target on shares of Hikma Pharmaceuticals Plc from GBX 1,600 ($26.84) to GBX 1,610 ($27.01) in a research note on Friday, August 1st. They now have a “hold” rating on the stock. Separately, analysts at Goldman Sachs upgraded shares of Hikma Pharmaceuticals Plc to a “buy” rating in a research note on Friday, July 18th. They now have a GBX 2,250 ($37.75) price target on the stock, up previously from GBX 1,800 ($30.20). Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Tuesday, June 17th. They now have a GBX 1,400 ($23.49) price target on the stock. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of GBX 1,770 ($29.69).
Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.